Josemaria Paterno, MD
Interventional Pain Medicine · Round Rock, TXNPI 1679885693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 984 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 82.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $4,745 and has fallen 77.8% since, to $1,052 in 2025.
Across 984 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$18K
- Boston Scientific$2K
- Medtronic$885
- Biodelivery Sciences International, Inc.$180
- Nalu Medical, Inc.$122
- Globus Medical$116
- plus $923 from 19 others
What the payments were for
- Food & beverage$21,254100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 807 | $17,515 |
| Boston Scientific | 101 | $1,513 |
| Medtronic(2 entities) | 13 | $885 |
| Biodelivery Sciences International, Inc. | 13 | $180 |
| Nalu Medical, Inc. | 1 | $122 |
| Globus Medical | 1 | $116 |
| Pfizer | 8 | $115 |
| Collegium Pharmaceutical, Inc. | 6 | $107 |
| Amgen(2 entities) | 4 | $92 |
| Protega Pharmaceutials Inc | 3 | $72 |
| SPR Therapeutics, Inc | 1 | $68 |
| GRT US Holding, Inc. | 3 | $59 |
| Radius Health, Inc. | 3 | $52 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| AbbVie | 2 | $36 |
| Forte Bio-pharma LLC | 3 | $35 |
| IBSA Pharma Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Scilex Pharmaceuticals Inc. | 2 | $29 |
| Tersera Therapeutics LLC | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Bristol Myers Squibb | 1 | $23 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$3,272
- Proclaim IPG$1,908
- OCTRODE$1,534
- Proclaim Family of SCS IPGs$797
- SYNCHROMEDII$351
- INTELLIS$154
- BELBUCA$124
- GENERAL PAIN MANAGEMENT$124
- Nalu Neurostimulation System$122
- Senza$116
How this compares
$21,254 in reported general payments places this provider in the 80th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,485 | $69,402 |
| Xtampza ErOxycodone Myristate | 117 | $53,870 |
| OxycontinOxycodone Hcl | 74 | $39,931 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 826 | $20,735 |
| BelbucaBuprenorphine Hcl | 15 | $12,825 |
| Morphine Sulfate ErMorphine Sulfate | 406 | $10,781 |
| Oxycodone Hcl | 530 | $8,862 |
| Fentanyl | 65 | $5,720 |
| Oxymorphone Hcl ErOxymorphone Hcl | 14 | $4,365 |
| Lidocaine | 19 | $2,764 |
| Gabapentin | 195 | $2,205 |
| Methadone Hcl | 94 | $1,742 |
| Hydromorphone Hcl | 148 | $1,631 |
| Buprenorphine | 12 | $1,591 |
| Morphine Sulfate | 62 | $1,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $107 | $66,696132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Round Rock
- Mark MaloneRound Rock$20K
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.1M
- Chad StephensSouthlake$1M
- Ankur KhoslaShenandoah$277K
- Brian RichDecatur$245K
- Brian BruelHouston$219K
- Bolkar SahinlerLubbock$188K
- Timothy RatinoFort Worth$139K
- Genaro GutierrezAustin$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.